TBI Long-Term Medication Management: What PI Attorneys Need to Know

James Wong — Founder & Pharmacist, LienScripts | February 15, 2026 | 8 min read

Mild-to-moderate traumatic brain injury triggers a 12-to-24-month medication journey spanning acute seizure prophylaxis, subacute cognitive and psychiatric treatment, and chronic migraine and sleep management. The pharmacy record is among the most powerful exhibits in any TBI personal injury case.

Traumatic Brain Injury Is a Long-Term Medical Event

When a personal injury attorney receives a new TBI case, the instinct is often to focus on the imaging — the CT scans, the MRI, the neuropsychological evaluation. These are important. But the medication record, built over the 12 to 24 or more months of active treatment, may be the single most persuasive document in the demand package for one simple reason: it is generated entirely by independent treating clinicians, updated at every prescription refill, and impossible to retroactively fabricate.

Mild-to-moderate traumatic brain injury — the range that encompasses the majority of PI TBI cases — does not follow a linear recovery curve. It follows a complex, phase-dependent clinical trajectory that requires different medications at different stages of recovery, creates a rich and layered pharmaceutical record, and produces documentable sequelae — cognitive symptoms, psychiatric comorbidities, headache disorders, sleep dysfunction — that persist long after the patient "looks fine" to outside observers.

Understanding that trajectory, phase by phase, is essential for any PI attorney who wants to build the strongest possible demand for a TBI client.

Phase One: Acute Management (Days to 4–6 Weeks)

The acute phase of TBI management begins at the emergency department or hospital and extends through the first weeks of outpatient follow-up. The medications prescribed during this phase establish the clinical baseline and document the treating team's assessment of injury severity.

Anti-Seizure Prophylaxis

Post-traumatic seizures are a recognized risk following moderate TBI, and anti-seizure prophylaxis is standard of care in the acute period. Levetiracetam (Keppra) is the most commonly prescribed agent — it is broad-spectrum, does not require blood level monitoring, and has a favorable tolerability profile compared to older agents like phenytoin.

A levetiracetam prescription in the acute phase documents that the treating physician assessed the patient's TBI as significant enough to warrant seizure prophylaxis — a clinical risk assessment that independently supports injury severity at the outset of the case. The prescription, dispensed through the pharmacy lien program, begins the documentary record at day one.

Valproate is sometimes used as an alternative, particularly when there are EEG abnormalities or when the physician prefers broader spectrum coverage. Either agent in the pharmacy record from the acute phase is documentation of a neurological risk assessment made in the context of diagnosed TBI.

Acute Headache Management

Post-traumatic headache is the most prevalent symptom following TBI, affecting the overwhelming majority of patients. In the acute phase, headache is managed with a combination of:

• NSAIDs (naproxen, ibuprofen at prescription doses, ketorolac) for mild-to-moderate episodes
• Triptans (sumatriptan, rizatriptan) for more severe headache episodes meeting migraine criteria
• Antiemetics (ondansetron, promethazine) for nausea associated with severe headache or vestibular symptoms
• Prescription-strength acetaminophen combinations where opioid-sparing approaches are used

The prescribing pattern in the acute phase establishes a baseline headache burden that is then tracked longitudinally through the pharmacy record. An attorney can point to the initiation of headache medications at week one and trace their continuation — with dose adjustments and medication additions — through month 18, demonstrating an unbroken thread of clinical headache management.

Phase Two: Subacute Management (6 Weeks to 6 Months)

The subacute phase is clinically complex and medically underappreciated by non-specialists. This is the period during which the brain's neuroplastic responses to injury are most active, when post-concussion syndrome either resolves or becomes entrenched, and when psychiatric and cognitive sequelae begin to crystallize into distinct clinical diagnoses.

Cognitive Medications

Some patients with moderate TBI — particularly those with frontal lobe involvement — experience clinically significant deficits in attention, processing speed, and working memory that affect their ability to work and manage daily activities. Specialist evaluation may lead to the use of:

• Amantadine: An NMDA receptor antagonist with dopaminergic properties, used off-label to support cognitive and functional recovery in TBI. Prescribing amantadine is a neurologist's or physiatrist's documented assessment that the patient's cognitive deficits are neurologically based and warrant pharmacological intervention.
• Stimulant medications (methylphenidate, amphetamine salts): Prescribed under specialist supervision for TBI-related attention and processing deficits. A controlled substance prescription for cognitive TBI sequelae represents a deliberate, documented clinical decision — one that carries significant evidential weight about the nature and severity of the underlying injury.
• Donepezil: Occasionally used off-label for cognitive rehabilitation in moderate TBI, particularly when memory deficits are prominent.

[!SOURCE] The use of stimulant medications and amantadine for TBI-related cognitive deficits is supported by research reviewed in the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) TBI model systems program. See TBI Model Systems publications via MSKTC.

Sleep Medications

Sleep architecture is profoundly disrupted by TBI. The injury affects the neurochemical systems that regulate sleep-wake cycles, producing insomnia, hypersomnia, fragmented sleep, or reversal of the sleep-wake cycle. Sleep disruption further impairs cognitive recovery, worsens mood disorders, and amplifies pain.

Trazodone is the most commonly prescribed non-habit-forming sleep agent in TBI. It provides sedation through serotonergic and histaminergic mechanisms without the dependence risk of benzodiazepines. A trazodone prescription that begins in the subacute phase and continues through 12 months documents persistent sleep dysfunction — a documented secondary injury consequence that supports damages for reduced quality of life and impaired cognitive recovery.

Melatonin at prescription doses, zolpidem (used cautiously for shorter periods), and low-dose quetiapine (prescribed by psychiatrists in patients with comorbid psychiatric symptoms) round out the sleep medication toolkit in TBI.

PTSD and Anxiety Medications

Motor vehicle accidents and other traumatic events that cause TBI frequently also cause PTSD and acute stress reactions. The psychiatric sequelae of TBI can be difficult to disentangle from pure PTSD — they often co-occur and interact. Medications prescribed for TBI-associated PTSD and anxiety include:

• SSRIs (sertraline, escitalopram): First-line for PTSD and anxiety. A sertraline prescription initiated at 6–8 weeks post-injury documents a treating clinician's assessment that the patient's psychological state was clinically significant at that time point.
• SNRIs (venlafaxine, duloxetine): Particularly useful when both mood symptoms and pain (including neuropathic features) need to be addressed simultaneously.
• Prazosin: Alpha-1 blocker prescribed specifically for PTSD-related nightmares, a relatively specific prescription signal with significant clinical meaning when present in the pharmacy record.
• Buspirone: Non-benzodiazepine anxiolytic for generalized anxiety features.

[!KEY] When the pharmacy record shows sertraline initiated at 8 weeks, prazosin added at 12 weeks, and trazodone running continuously throughout — all prescribed by the treating psychiatrist or neurologist — this is an independent clinical corroboration of the patient's reported psychological suffering that is far more persuasive to an adjuster than the plaintiff's testimony about their emotional state.

Phase Three: Chronic Management (6 Months to 18+ Months)

Patients with moderate TBI — and a meaningful fraction of those with mild TBI — enter a chronic phase that extends well past the six-month mark. In this phase, headache disorders, sleep dysfunction, psychiatric comorbidities, and cognitive symptoms have declared themselves as persistent conditions requiring sustained pharmaceutical management.

CGRP Inhibitors for Chronic Post-Traumatic Migraine

Post-traumatic migraine is a recognized complication of TBI that can persist for years. When episodic post-traumatic headache transitions into chronic migraine — defined as 15 or more headache days per month with at least 8 meeting migraine criteria — preventive therapy with CGRP inhibitors becomes the standard of care.

Erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality) are injectable monoclonal antibodies administered monthly or quarterly. They are expensive, require prior authorization, and are specifically prescribed by neurologists and headache specialists. A CGRP inhibitor in the pharmacy record from month 8 onward is one of the most powerful clinical markers of severe, persistent post-traumatic migraine — it documents that a specialist independently assessed the headache burden as warranting the most sophisticated class of preventive migraine therapy currently available.

Antidepressants as Long-Term Maintenance

SSRIs and SNRIs initiated in the subacute phase frequently continue through the chronic phase as maintenance therapy. The continuous refill record for sertraline from month 2 through month 20 is documentary evidence of a treating clinician's ongoing assessment that the patient's mood and anxiety symptoms required sustained pharmacological management throughout that period.

Sleep Agents as Ongoing Necessity

Trazodone, melatonin, and — under specialist management — other sleep agents continue into the chronic phase when sleep architecture has not normalized. The presence of sleep medications in the pharmacy record at month 18 documents that the TBI's effects on sleep physiology have not resolved — an important component of ongoing quality-of-life damages.

[!KEY] A pharmacy record spanning 18 months for a TBI patient — capturing levetiracetam in the acute phase, amantadine and an SSRI in the subacute phase, and CGRP inhibitors plus maintenance sertraline and trazodone in the chronic phase — is a structured, phase-by-phase exhibit that demonstrates injury severity, treatment necessity, and the realistic forward-looking medication burden that supports future medical expenses claims.

Why TBI Patients With Long Pharmacy Records Get Better Settlements

There is a direct clinical and legal logic connecting the length and complexity of the TBI pharmacy record to settlement value:

Duration of treatment is one of the most important inputs into special damages calculations. Each month in the pharmacy record represents physician-assessed, treatment-requiring ongoing injury. An 18-month pharmacy record supports an 18-month past medical expenses claim in the medication category, and — for patients still on active medication at settlement — supports ongoing future medication expense projections.

Phase complexity demonstrates injury severity. A pharmacy record that progresses through acute seizure prophylaxis, subacute psychiatric and cognitive management, and chronic migraine prevention is the pharmacological signature of moderate TBI — not a mild concussion that resolved in six weeks.

Multi-specialty involvement is documented through the prescription roster. A neurologist prescribes levetiracetam and CGRP inhibitors. A psychiatrist prescribes sertraline and prazosin. A physiatrist or sleep specialist manages trazodone and amantadine. The presence of multiple specialist prescribers in the pharmacy record corroborates the multi-system impact of the injury.

Pharmacy Lien Ensures Continuous Access Through the Full Arc

TBI medication management is expensive. The psychiatric medications, the sleep agents, and — particularly — the CGRP inhibitor biologics represent a significant financial burden for an uninsured or underinsured injured patient. Without medication access, patients stop treatment. Treatment gaps interrupt the record, invite defense challenges to continuity of care, and — more importantly — leave patients without the medications they need to support their recovery.

LienScripts pharmacy liens cover all physician-prescribed TBI medications from the acute phase through case resolution, with no out-of-pocket cost to the patient. The resulting record is a comprehensive, organized, chronological exhibit that reflects the full clinical arc of the TBI.

Related Resources

• Concussion and Mild TBI Medications: What to Expect on a Pharmacy Lien
• Ondansetron for Nausea After TBI: Clinical Guide
• What Is a CGRP Inhibitor and Why Does It Matter in a Post-Traumatic Migraine PI Case?